Abstract
Schizophrenia is a serious neuropsychiatric disease of uncertain etiology. Previous studies have demonstrated that antibodies to Toxoplasma gondii infection are associated with an increased risk of schizophrenia. The objective of this study was to analyze anti-T. gondii antibodies in 477 Chinese schizophrenia patients using an enzyme-linked immunosorbent assay (ELISA) based on recombinant surface antigen 1 (rSAG1), recombinant bradyzoite antigen 1 (rBAG1) and the soluble tachyzoite antigens (STAg) of T. gondii RH strain. Results showed that among the sero-positives (IgG and/or IgM) for T. gondii infection examined in schizophrenia patients, sero-positive samples for rSAG1, rBAG1 and STAg were 20.5% (98/477), 20.5% (98/477) and 23.5% (112/477) respectively, while compared to 210 blood donors, sero-positive (IgG and/or IgM) samples for these antigens (rSAG1, rBAG1 and STAg) were only 5.7% (12/210), 6.2% (13/210) and 5.7% (12/210), respectively. Furthermore, when IgG antibody reaction in the schizophrenia sera was compared with the rBAG1 and rSAG1, results demonstrated that beside the cases which can be detected by both rSAG1 and rBAG1, some sero-positive for T. gondii in schizophrenia sera can only be detected either by rSAG1 or rBAG1. This phenomenon was also observed in the detection of IgM with rSAG1 and rBAG1. 5.9% (28/477) of cases of schizophrenia which are positive for IgG or IgM by rSAG1 are negative for STAg, while 9.2% (44/477) of the schizophrenia cases which are positive for IgG or IgM by rBAG1 are negative for STAg. Although STAg can also be used to diagnose T. gondii infection from schizophrenia patients, it may not actually indicate the infection as some positive samples may be mistakenly considered to be negative. In conclusion, our results demonstrate that the sero-positive rate for T. gondii in the Chinese schizophrenia patients was higher than blood donors. More importantly, our results provide evidence that the combination of rSAG1 and rBAG1 antigens in the diagnosis of T. gondii infection could closely reflect the actual infection of this parasite in schizophrenia patients.
[1] Boothroyd J.C. 2009. Expansion of host range as a driving force in the evolution of Toxoplasma. Memórias do Instituto Oswaldo Cruz, 104, 179–184. DOI: 10.1590/S0074-02762009000200009. http://dx.doi.org/10.1590/S0074-0276200900020000910.1590/S0074-02762009000200009Search in Google Scholar PubMed
[2] Brown A.S., Schaefer C.A., Liu L., Babulas V.P., Susser E.S. 2005. Maternal exposure to toxoplasmosis and risk of schizophrenia in adult offspring. American Journal of Psychiatry, 162, 767–773. http://dx.doi.org/10.1176/appi.ajp.162.4.76710.1176/appi.ajp.162.4.767Search in Google Scholar PubMed
[3] Cui J.Z. 2000. Researches on toxoplasmosis for ninety years. Journal of Practical Parasitosis, 2, 75–78. Search in Google Scholar
[4] Chen X.G., Wu K., Lun Z.R. 2005. Toxoplasmosis researches in China. Chinese Medical Journal, 118, 1007–1014. Search in Google Scholar
[5] Curruthers V.B., Suzuki Y. 2007. Effects of Toxoplasma gondii infection on the brain. Schizophrenia Bulletin, 33, 745–751. DOI: 10.1093/schbul/sbm008. http://dx.doi.org/10.1093/schbul/sbm00810.1093/schbul/sbm008Search in Google Scholar PubMed PubMed Central
[6] Derouin F., Pelloux H. 2008. Prevention of toxoplasmosis in transplant patients. Clinical Microbiology and Infection, 14, 1089–1101. DOI: 10.1111/j.1469-0691.2008.02091.x. http://dx.doi.org/10.1111/j.1469-0691.2008.02091.x10.1111/j.1469-0691.2008.02091.xSearch in Google Scholar PubMed
[7] Dubey J.P., Lindsay D.S., Lappin M.R. 2009. Toxoplasmosis and other intestinal coccidial infections in cats and dogs. Veterinary Clinics of North America. Small Animal Practice, 39, 1009–1034. DOI: 10.1016/j.cvsm.2009.08.001. http://dx.doi.org/10.1016/j.cvsm.2009.08.00110.1016/j.cvsm.2009.08.001Search in Google Scholar PubMed
[8] Fernandes R.C., Vasconcellos V.P., Araújo L.C., Medina-Acosta E. 2009. Vertical transmission of HIV and Toxoplasma by reactivation in a chronically infected woman. Brazilian Journal of Infectious Diseases, 13, 70–71. DOI: 10.1590/S1413-86702009000100015. http://dx.doi.org/10.1590/S1413-8670200900010001510.1590/S1413-86702009000100015Search in Google Scholar
[9] Freedman R. 2003. Schizophrenia. New England Journal of Medicine, 349, 1738–1749. http://dx.doi.org/10.1056/NEJMra03545810.1056/NEJMra035458Search in Google Scholar PubMed
[10] Fouts A.E., Boothroyd J.C. 2007. Infection with Toxoplasma gondii bradyzoites has a diminished impact on host transcript levels relative to tachyzoite infection. Infection and Immunity, 75, 634–642. DOI: 10.1128/IAI.01228-06. http://dx.doi.org/10.1128/IAI.01228-0610.1128/IAI.01228-06Search in Google Scholar PubMed PubMed Central
[11] Kim S.K., Boothroyd J.C. 2005. Stage-specific expression of surface antigens by Toxoplasma gondii as a mechanism to facilitate parasite persistence. Infection and Immunity, 174, 8038–8048. Search in Google Scholar
[12] Lafferty K.D. 2006. Can the common brain parasite, Toxoplasma gondii, influence human culture? Proceedings. Biological Sciences, 273, 2749–2755. DOI: 10.1098/rspb.2006.3641. http://dx.doi.org/10.1098/rspb.2006.364110.1098/rspb.2006.3641Search in Google Scholar PubMed PubMed Central
[13] Liu S., Zhang C.Y. 2006. Pets:canis and cats and toxoplasmosis. Breeding Canis, 62, 19–20. Search in Google Scholar
[14] Mao Y., Ge X., Frank C.L., Madison J.M., Koehler A.N., Doud M.K., Tassa C., Berry E.M., Soda T., Singh K.K., Biechele T., Petryshen T.L., Moon R.T., Haggarty S.J., Tsai L.H. 2009. Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3β/β-catenin signaling. Cell, 136, 1017–1031. DOI: 10.1016/j.cell.2008.12.044. http://dx.doi.org/10.1016/j.cell.2008.12.04410.1016/j.cell.2008.12.044Search in Google Scholar PubMed PubMed Central
[15] Mortensen P.B., Nørgaard-Pedersen B., Waltoft B.L., Sørensen T.L., Hougaard D., Yolken R.H. 2007. Early infections of Toxoplasma gondii and the later development of schizophrenia. Schizophrenia Bulletin, 33, 741–744. DOI: 10.1093/schbul/sbm009. http://dx.doi.org/10.1093/schbul/sbm00910.1093/schbul/sbm009Search in Google Scholar PubMed PubMed Central
[16] Pappas G., Roussos N., Falagas M.E. 2009. Toxoplasmosis snapshots: Global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosis. International Journal for Parasitology, 39, 1385–1394. DOI: 10.1016/j.ijpara.2009.04.003. http://dx.doi.org/10.1016/j.ijpara.2009.04.00310.1016/j.ijpara.2009.04.003Search in Google Scholar PubMed
[17] Saeij J.P., Boyle J.P., Boothroyd J.C. 2005. Differences among the three major strains of Toxoplasma gondii and their specific interactions with the infected host. Trends in Parasitology, 21, 476–481. DOI: 10.1016/j.pt.2005.08.001. http://dx.doi.org/10.1016/j.pt.2005.08.00110.1016/j.pt.2005.08.001Search in Google Scholar PubMed
[18] Stefansson H., Sigurdsson E., Stefansson K. 2002. Neuregulin 1 and susceptibility to schizophrenia. American Journal of Human Genetics, 71, 877–892. DOI: 10.1086/342734. http://dx.doi.org/10.1086/34273410.1086/342734Search in Google Scholar PubMed PubMed Central
[19] Tamer G.S., Dundar D., Yalug I., Caliskan S., Yazar S., Aker A. 2008. The schizophrenia and Toxoplasma gondii connection: infectious, immune or both? Advances in Therapy, 25, 703–709. DOI: 10.1007/s12325-008-0063-5. http://dx.doi.org/10.1007/s12325-008-0063-510.1007/s12325-008-0063-5Search in Google Scholar PubMed
[20] Torrey E.F., Yolken R.H. 2003. Toxoplasma gondii and schizophrenia. Emerging Infectious Diseases, 9, 1375–1380. Search in Google Scholar
[21] Torrey E.F., Bartko J.J., Lun Z.R., Yolken R.H. 2007. Antibodies to Toxoplasma gondii in patients with schizophrenia: a metaanalysis. Schizophrenia Bulletin, 33, 729–736. DOI: 10.1093/schbul/sbl050. http://dx.doi.org/10.1093/schbul/sbl05010.1093/schbul/sbl050Search in Google Scholar PubMed PubMed Central
[22] Wang Q., Wu K., Chen X.G., Hao L., Cheng L. 2007. Cloning and expression of a bradyzoite-specific gene of Toxoplasma gondii and immunoreactive analysis on the recombinant antigen. Chinese Journal of Parasitology and Parasitic Diseases, 25, 295–299. Search in Google Scholar
[23] Wu K., Chen X.G., Li H., Yan H., Yang P.L., Lun Z.R., Zhu X.Q. 2009. Diagnosis of human toxoplasmosis by using the recombinant truncated surface antigen 1 of Toxoplasma gondii. Diagnostic Microbiology and Infectious Disease, 64, 261–266. DOI: 10.1016/j.diagmicrobio.2009.02.009. http://dx.doi.org/10.1016/j.diagmicrobio.2009.02.00910.1016/j.diagmicrobio.2009.02.009Search in Google Scholar PubMed
[24] Xiao J.C., Buka S.L., Cannon T.D., Suzuki Y., Viscidi R.P., Torrey E.F., Yolken R.H. 2009. Serological pattern consistent with infection with type I Toxoplasma gondii in mothers and risk of psychosis among adult offspring. Microbes and Infection, 11, 1011–1018. DOI: 10.1016/j.micinf.2009.07.007. http://dx.doi.org/10.1016/j.micinf.2009.07.00710.1016/j.micinf.2009.07.007Search in Google Scholar PubMed
[25] Xu L.Q., Chen Y.D., Sun F.H., Cai N., Fang Y.Y., Wang L.P., Liu X., Li L.S., Feng Y., Li H. 2005. A national survey on current status of the important parasitic diseases in human population. Chinese Journal of Parasitology and Parasitic Diseases, 23, 332–340. Search in Google Scholar
[26] Yolken R.H., Bachmann S., Roudlanova I., Lillehoj E., Ford G., Torrey E.F., Schroeder J. 2001. Antibodies to Toxoplasma gondii in individuals with first-episode schizophrenia. Clinical Infectious Diseases, 32, 842–844. DOI: 1058-4838/2001/3205-0028. http://dx.doi.org/10.1086/31922110.1086/319221Search in Google Scholar PubMed
[27] Yolken R.H., Dickerson F.B., Torrey E.F. 2009. Toxoplasma and schizophrenia. Parasite Immunology, 31, 706–715. DOI: 10.1111/j.1365-3024.2009.01131.x. http://dx.doi.org/10.1111/j.1365-3024.2009.01131.x10.1111/j.1365-3024.2009.01131.xSearch in Google Scholar PubMed
© 2011 W. Stefański Institute of Parasitology, PAS
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
